Identification of uniquely expressed transcription factors in highly purified B-cell lymphoma samples

American Journal of Hematology

Volumn 85, Issue 6, 2010, Pages 418-425

  Andréasson, Ulrika ^a   Edén, Patrik ^a   Peterson, Carsten ^a   Högerkorp, Carl Magnus ^a   Jerkeman, Mats ^a,b   Andersen, Niels ^c   Berglund, Mattias ^d   Sundström, Christer ^d   Rosenquist, Richard ^d   Borrebaeck, Carl A K ^a   Ek, Sara ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c University of Copenhagen   (Denmark)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR;

ARTICLE; B CELL LYMPHOMA; CANCER CELL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; GENE EXPRESSION PROFILING; HAIRY CELL LEUKEMIA; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

B-LYMPHOCYTE SUBSETS; CELL SEPARATION; CLUSTER ANALYSIS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, B-CELL; NEOPLASM PROTEINS; RNA, MESSENGER; RNA, NEOPLASM; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 77953067050     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21701     Document Type: Article

References (73)

1. Lebien TW, Tedder TF. B lymphocytes: How they develop and function. Blood 2008;112:1570-1580.
2. Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: The microscope as a tool for disease discovery. Blood 2008;112:4384-4399.
3. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
4. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947.
5. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003d;3:185-197.
6. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159-2169.
7. De Jong D. Molecular pathogenesis of follicular lymphoma: A cross talk of genetic and immunologic factors. J Clin Oncol 2005;23:6358-6363. (Pubitemid 46218847)
8. Glas AM, Knoops L, Delahaye L, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007;25:390-398.
9. Zhang J, Jima DD, Jacobs C, et al. Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood 2009;113:4586-4594.
10. Nutt SL, Heavey B, Rolink AG, Busslinger M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 1999;401:556-562. (Pubitemid 129517063)
11. Chang CC, Ye BH, Chaganti RS, Dalla-Favera R. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proc Natl Acad Sci USA 1996;93:6947-6952. (Pubitemid 26243480)
12. Shaffer AL, Emre NC, Romesser PB, Staudt LM. IRF4: Immunity. Malignancy! Therapy?. Clin Cancer Res 2009;15:2954-2961.
13. Turner CA, Mack DH, Davis MM. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin- secreting cells. Cell 1994;77:297-306.
14. Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 2004;21:81-93.
15. Ek S, Dictor M, Jerkeman M, et al. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood 2008;111:800-805.
16. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Lyon, France: International Agency for resarch on Cancer; 2008.
17. Andreasson U, Dictor M, Jerkeman M, et al. Identification of molecula targets associated with transformed diffuse large B cell Lymphoma using highly purified tumour cells. Am J Hematology 2009;84.
18. Berglund M, Thunberg U, Amini RM, et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 2005;18:1113-1120.
19. Hans CP, Weisenburger DD, Vose JM, et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 2003;101:2363-2367.
20. Andreasson U, Ek S, Merz H, et al. B cell lymphomas express CX3CR1 a non-B cell lineage adhesion molecule. Cancer Lett 2008;259:138-145.
21. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B (Statistical Methodol 1995;289-300.
22. Bouchard C, Lee S, Paulus-Hock V, et al. FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf. Genes Dev 2007;21:2775-2787. (Pubitemid 350070723)
23. Liu Z, Oh SM, Okada M, et al. Human BRE1 is an E3 ubiquitin ligase for Ebp1 tumor suppressor. Mol Biol Cell 2009;20:757-768.
24. Gustavsson E, Sernbo S, Andersson E, et al. Sox11 Functions as a Tumor Suppressor Under Epigenetic Control in Mantle Cell Lymphomas, Lund: Immunotechnology; 2009.
25. Canote R, Du Y, Carling T, et al. The tumor suppressor gene RIZ in cancer gene therapy (review). Oncol Rep 2002;9:57-60.
26. Baron V, Adamson ED, Calogero A, et al. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther 2006;13:115-124. (Pubitemid 43113412)
27. Gibbs JD, Liebermann DA, Hoffman B. Egr-1 abrogates the E2F-1 block in terminal myeloid differentiation and suppresses leukemia. Oncogene 2008;27:98-106.
28. Gibbs JD, Liebermann DA, Hoffman B. Leukemia suppressor function of Egr-1 is dependent on transforming oncogene. Leukemia 2008;22:1909-1916.
29. Pan X, Zhao J, Zhang WN, et al. Induction of SOX4 by DNA damage is critical for p53 stabilization and function. Proc Natl Acad Sci USA 2009;106:3788-3793.
30. Pramoonjago P, Baras AS, Moskaluk CA. Knockdown of Sox4 expression by RNAi induces apoptosis in ACC3 cells. Oncogene 2006;25:5626-5639. (Pubitemid 44387618)
31. Zheng C, Ren Z, Wang H, et al. E2F1 Induces tumor cell survival via nuclear factor-kappaB-dependent induction of EGR1 transcription in prostate cancer cells. Cancer Res 2009;69:2324-2331.
32. Rayoo M, Yan M, Takano EA, et al. Expression of the forkhead box transcription factor FOXP1 is associated with estrogen receptor alpha, estrogen receptor beta and improved survival in familial breast cancers. J Clin Pathol 2009;84:803-808.
33. Lam LT, Davis RE, Pierce J, et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005;11:28-40.
34. Basso K, Liso A, Tiacci E, et al. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med 2004;199:59-68.
35. Hedge SP, Kumar A, Kurschner C, Shapiro LH. c-Maf interacts with c-Myb to regulate transcription of an early myeloid gene during differentiation. Mol Cell Biol 1998;18:2729-2737. (Pubitemid 28183442)
36. Hegde SP, Zhao J, Ashmun RA, Shapiro LH. c-Maf induces monocytic differentiation and apoptosis in bipotent myeloid progenitors. Blood 1999;94:1578-1589. (Pubitemid 29411308)
37. Yu S, Matsusue K, Kashireddy P, et al. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem 2003;278:498-505. (Pubitemid 36043602)
38. Drori S, Girnun GD, Tou L, et al. Hic-5 regulates an epithelial program mediated by PPARgamma. Genes Dev 2005;19:362-375. (Pubitemid 40189299)
39. Goudreau G, Petrou P, Reneker LW, et al. Mutually regulated expression of Pax6 and Six3 and its implications for the Pax6 haploinsufficient lens phenotype. Proc Natl Acad Sci USA 2002;99:8719-8724.
40. Sundrud MS, Grill SM, Ni D, et al. Genetic reprogramming of primary human T cells reveals functional plasticity in Th cell differentiation. J Immunol 2003;171:3542-3549.
41. D'amico M, Hulit J, Amanatullah DF, et al. The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3beta and cAMP-responsive element-binding protein-dependent pathways. J Biol Chem 2000;275:32649-32657.
42. Ohtani K, Degregori J, Nevins JR. Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci USA 1995;92:12146-12150. (Pubitemid 26014027)
43. Chaganti RS, Nanjangud G, Schmidt H, Teruya-Feldstein J. Recurring chromosomal abnormalities in non-Hodgkin's lymphoma: Biologic and clinical significance. Semin Hematol 2000;37:396-411.
44. Davies AJ, Rosenwald A, Wright G, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol 2007;136:286-293.
45. Rosenwald A, Staudt LM. Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma 2003b;44:(Suppl 3)S41-47.
46. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001;194:1625-1638.
47. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-1647.
48. Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: The dark side of B-cell differentiation. Nat Rev Immunol 2002;2:920-932. (Pubitemid 37323213)
49. Ek S, Högerkorp CM, Dictor M, et al. Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Res 2002;62:4398-4405. (Pubitemid 34827299)
50. Ellmark P, Högerkorp CM, Ek S, et al. Phenotypic protein profiling of different B cell sub-populations using antibody CD-microarrays. Cancer Lett 2008;265:98-106.
51. Pascual V, Liu YJ, Banchereau J. Normal human B cell sub-populations and their malignant counterparts. Baillieres Clin Haematol 1997;10:525-538. (Pubitemid 27488821)
52. Rosenwald A. DNA microarrays in lymphoid malignancies. Oncology 2003a; 17:1743-1748; discussion 1750, 1755, 1758-11749
53. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009;113:6069-6076.
54. Libermann TA, Zerbini LF. Targeting transcription factors for cancer gene therapy. Curr Gene Ther 2006;6:17-33.
55. Jansen J, Meijer CJ, Van Der Valk P, et al. Phagocytic potential of hairy cells. Scand J Haematol 1979;23:69-79.
56. Rosner MC, Golomb HM. Phagocytic capacity of hairy cells from seventeen patients. Virchows Arch B Cell Pathol Incl Mol Pathol 1982;40:327-337.
57. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
58. Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003;100:9991-9996. (Pubitemid 37087056)
59. Kuppers R, Klein U, Hansmann ML, Rajewsky K. Cellular origin of human B-cell lymphomas. N Engl J Med 1999;341:1520-1529. (Pubitemid 29526356)
60. Ott G, Rosenwald A. Molecular pathogenesis of follicular lymphoma. Haematologica 2008;93:1773-1776.
61. Godon A, Moreau A, Talmant P, et al. Is t(14;18)(q32;q21) a constant finding in follicular lymphoma? An interphase FISH study on 63 patients. Leukemia 2003;17:255-259.
62. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392. (Pubitemid 24273002)
63. Martinez-Climent JA, Vizcarra E, Sanchez D, et al. Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma. Blood 2001;98:3479-3482.
64. Vizcarra E, Martinez-Climent JA, Benet I, et al. Identification of two sub-groups of mantle cell leukemia with distinct clinical and biological features. Hematol J 2001;2:234-241.
65. Iida S, Rao PH, Butler M, et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 1997;17:226-230.
66. Ito M, Iida S, Inagaki H, et al. MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Jpn J Cancer Res 2002;93:685-694.
67. Tsuboi K, Iida S, Inagaki H, et al. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia 2000;14:449-456.
68. Di Bernardo MC, Crowther-Swanepoel D, Broderick P, et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet 2008;40:1204-1210.
69. Shaffer AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature 2008;454:226-231.
70. Tierens A, Delabie J, Malecka A, et al. Splenic marginal zone lymphoma with villous lymphocytes shows on-going immunoglobulin gene mutations. Am J Pathol 2003;162:681-689. (Pubitemid 36267875)
71. Walsh SH, Rosenquist R. Immunoglobulin gene analysis of mature B-cell malignancies: reconsideration of cellular origin and potential antigen involvement in pathogenesis. Med Oncol 2005;22:327-341. (Pubitemid 43780289)
72. Vanhentenrijk V, De Wolf-Peeters C, Wlodarska I. Comparative expressed sequence hybridization studies of hairy cell leukemia show uniform expression profile and imprint of spleen signature. Blood 2004;104:250-255. (Pubitemid 38879865)
73. Vanhentenrijk V, Tierens A, Wlodarska I, et al. V(H) gene analysis of hairy cell leukemia reveals a homogeneous mutation status and suggests its marginal zone B-cell origin. Leukemia 2004;18:1729-1732.